These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 10863108

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
    Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF.
    J Antimicrob Chemother; 1999 Dec; 44(6):749-59. PubMed ID: 10590275
    [Abstract] [Full Text] [Related]

  • 9. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H, Vilches V, Scarano S, Stepanik D, Smayevsky J, Lemme L, Cardeñosa O, Ambler J, Sucari A.
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN, SENTRY Study Group (Latin America).
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [Abstract] [Full Text] [Related]

  • 13. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
    Marchese A, Debbia EA, Schito GC.
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
    [Abstract] [Full Text] [Related]

  • 15. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
    Dorai-John T, Thomson CJ, Amyes SG.
    J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY antimicrobial surveillance program 1997. SENTRY Participants Group.
    Fluit AC, Schmitz FJ, Jones ME, Acar J, Gupta R, Verhoef J.
    Int J Infect Dis; 1999 Feb; 3(3):153-6. PubMed ID: 10460927
    [Abstract] [Full Text] [Related]

  • 17. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J, Fernandes ML, Serrano N, Grupo de Estudo Português de Bactérias Patogénicas Respiratórias.
    Acta Med Port; 2001 Jul; 14(5-6):459-68. PubMed ID: 11878155
    [Abstract] [Full Text] [Related]

  • 20. Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland.
    Betlejewska K, Hryniewicz W.
    Int J Antimicrob Agents; 2002 Jan; 19(1):47-52. PubMed ID: 11814767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.